Glaukos Corporation Stock News

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Glaukos' (GKOS) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Glaukos (GKOS) announces the receipt of a permanent J-code for iDose TR from the CMS, which is likely to boost the billing and payment process.

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Glaukos' (GKOS) fourth-quarter revenues beat estimates as well as gained year over year. Gross margin improve, while higher operating expenses lead to a wider operating loss.

Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript

Glaukos (GKOS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.53 per share a year ago.

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Glaukos' (GKOS) revenues in the fourth quarter have been primarily driven by the continued demand for existing and newly launched products.

The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.